Results 171 to 180 of about 1,503,737 (251)
Establishment of a Sensitized 3D Spheroid Cancer Cell Model for Enhanced Anti-Cancer Drug Discovery. [PDF]
Tan EW, Goh TY, Law SH, Tan KO, Goh BH.
europepmc +1 more source
Objective This study aimed to characterize cannabis product choices (cannabinoid content and formulation) among patients with rheumatologic conditions and their associations with patient factors, patient‐reported perceived side effects, and positive impacts.
Susan Zhang +10 more
wiley +1 more source
The Roles of Exosomes in Anti-Cancer Drugs. [PDF]
Feng P, Zhang X, Gao J, Jiang L, Li Y.
europepmc +1 more source
Objective Studies of damage accrual in patients with systemic lupus erythematosus (SLE) show associations with disease activity measured by the SLE Disease Activity Index 2000 (SLEDAI‐2K), but these associations are imperfect. SLEDAI scores are powerfully influenced by weightings (1–8) assigned to each domain.
Kevin Zhang +8 more
wiley +1 more source
A Double-Edged Role for SIRT7 in Cancer: Can Anti-Cancer Immunity Tip the Balance? [PDF]
Tarighi S +5 more
europepmc +1 more source
Objective We characterized emergency department (ED) gout visits and identified patient characteristics and health services patterns contributing to ED presentations. Methods We conducted a population‐based study of ED gout visits in Ontario, Canada, between 2014 and 2023.
Timothy S. H. Kwok +7 more
wiley +1 more source
Retraction of: Tiny Bryophytes: Nature's Hidden Reservoirs of Powerful Anti-Cancer Compounds. [PDF]
europepmc +1 more source
Editorial: Discovery of small molecule lead compounds: a driving force to unravel new anti-cancer targets and mechanisms, volume III. [PDF]
Zhang Y, Fu L, Wang Y.
europepmc +1 more source
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato +27 more
wiley +1 more source
An up-to-date review of decursin and its anti-cancer activities. [PDF]
Park CH.
europepmc +1 more source

